News
Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer The authors report on a prognostic tool (CD3 ...
eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) ...
Abbreviations: ALP, alkaline phosphatase; ANC, absolute neutrophil count; CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group; HGB, hemoglobin ...
Associations between acupuncture and uses of opioids and neuropsychiatric medication following chemotherapy-induced peripheral neuropathy among patients with breast cancer. Pool analysis of Part A ...
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...
Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round In a tumor agnostic fashion, cfDNA for ...
Patients were randomly assigned 1:1 (stratified by histology, best response to last anti–PD-(L)1–containing regimen, and AGA treatment received or not) to SG (one 10 mg/kg intravenous infusion on days ...
Addressing Barriers in Palliative Care for Rural and Underserved Communities Changes to sexual function after cancer treatment are extremely prevalent, affecting up to 90% of female patients with ...
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study Cohort 2 included 38 patients (61% male; median age 72.5 ...
Patients received Dato-DXd 6 mg/kg once every 3 weeks. The primary end point was objective response rate (ORR) by blinded independent central review. Secondary end points included duration of response ...
Immune Checkpoint Combos in Metastatic Castration-Resistant Prostate Cancer: Where Are We Going, What Are We Doing, and Why? The following represents disclosure information provided by authors of this ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results